Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer. Nierengarten MB. Cancer 2024;130:2246.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer. Cancer 2024;130:2246.
PMID: 38849630